Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY off to another strong start in the markets

<< Previous

Bullboard Posts

Next >>

Comment by Peladawnon Dec 17, 2024 9:56am

86 Views

Post# 36366033

RE:ONCY off to another strong start in the markets

What a surprise....as soon as another large fake "sell" goes through, Quentin shows up to once again bash about how oncy hasn't done a deal.....maybe if you or one of your kids are diagnosed with pancreatic cancer, maybe then you'll finally stfu.

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal